Summary of use during lactation
No information is available on the clinical use of solriamfetol during breastfeeding. However, amounts in breastmilk appear to be low and would not be expected to cause any adverse effects in breastfed infants. If solriamfetol is required by the mother, it is not a reason to discontinue breastfeeding. Monitor the breastfed infant for adverse reactions, such agitation, insomnia, and reduced weight gain.
Drug levels in milk and infant serum
Maternal Levels. The manufacturer reports that a single-dose milk and plasma lactation study was conducted in 6 healthy adult lactating women who were between 10 days and 52 weeks postpartum. They were given a single oral 150 mg dose of solriamfetol. The daily infant dose is 0.112 mg/kg based on infant weight of 6 kg. The cumulative median amount excreted in breastmilk was 0.67 mg over 72 hours, which is about 5.5% of the weight-adjusted maternal dose. Of the total amount of solriamfetol excreted in breastmilk over 72 hours, approximately 78% and 98% were excreted by 8 and 24 hours, respectively, with an apparent mean elimination half-life in breast milk of about 5 hours. Infant Levels. Relevant published information was not found as of the revision date.
Effects in breastfed infants
Relevant published information was not found as of the revision date.
Effects on lactation and breastmilk
Relevant published information was not found as of the revision date.
Alternative drugs to consider
(Narcolepsy) Amphetamine, Armodafinil, Dextroamphetamine, Lisdexamfetamine, Methylphenidate, Modafinil, Oxybate Salts, Pitolisant
Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.
Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.